Lin Peng-Tao, Chen Wen-Hua, Zheng Hong, Lai Zhong-Meng, Zhang Liang-Cheng
Department of Anesthesiology, Fujian Medical University Union Hospital Fujian, China.
Int J Clin Exp Med. 2015 Aug 15;8(8):12736-45. eCollection 2015.
our research aim to study the role of AQP1 in the cardioprotective effect of remifentanil post-conditioning for myocardial ischemia/reperfusion injury.
Ninety Sprague-Dawley (SD) rats were divided into 6 groups: sham operation group (Sham group), myocardial ischemia and reperfusion group (I/R group), postconditioning of remifentanil group (R-post), postconditioning of remifentanil plus AQP1 inhibitor acetazolamide group (R-post +Ace), postconditioning of remifentanil plus opioid-receptor antagonist compounds (R-post +AC), postconditioning of remifentanil plus AQP1 enhancer arginine vasopressin (R-post +AV). All groups except the sham operation group were given 30 min ischemia in left anterior descending (LAD) coronary arteries. All groups were then given 120 min reperfusion to the LAD. Before reperfusion, the R-post, R-post +Ace, R-post +AC, R-post +AV groups were given 10 min remifentanil post-conditioning. Hemodynamic data were measured every 30 min after initiation of ischemia. The rats' hearts were exercised for detecting infarct size and water content in the left ventricle, and AQP1 expression were also detected.
The R-post group showed a significant reduction of the infarct size compared to the I/R group. The effect of R-post for reducing infarct size was slightly enhanced by adding acetazolamide to R-post, so significant differences could still be found when compared R-post+Ace group to the I/R group. The effect of infarct size reduction brought by R-post was blocked by the opioid-receptor antagonist compounds. This effect was also blocked by the AQP1 enhancer. Similar outcomes were found considering the water content of the left ventricle and the AQP1 expression.
Cardioprotective effect of remifentanil post-conditioning may initiate through inhibiting the function of AQP1.
我们的研究旨在探讨水通道蛋白1(AQP1)在瑞芬太尼后处理对心肌缺血/再灌注损伤的心脏保护作用中的作用。
将90只Sprague-Dawley(SD)大鼠分为6组:假手术组(Sham组)、心肌缺血再灌注组(I/R组)、瑞芬太尼后处理组(R-post)、瑞芬太尼加AQP1抑制剂乙酰唑胺后处理组(R-post +Ace)、瑞芬太尼加阿片受体拮抗剂化合物后处理组(R-post +AC)、瑞芬太尼加AQP1增强剂精氨酸加压素后处理组(R-post +AV)。除假手术组外,其余各组均采用冠状动脉左前降支(LAD)30分钟缺血处理。然后对所有组的LAD进行120分钟再灌注。再灌注前,R-post、R-post +Ace、R-post +AC、R-post +AV组给予10分钟瑞芬太尼后处理。缺血开始后每30分钟测量血流动力学数据。对大鼠心脏进行检测以测定梗死面积和左心室含水量,并检测AQP1表达。
与I/R组相比,R-post组梗死面积显著减小。在R-post中加入乙酰唑胺可使R-post减小梗死面积的作用略有增强,因此R-post+Ace组与I/R组相比仍有显著差异。R-post带来的梗死面积减小作用被阿片受体拮抗剂化合物阻断。这种作用也被AQP1增强剂阻断。考虑左心室含水量和AQP1表达时发现了类似结果。
瑞芬太尼后处理的心脏保护作用可能通过抑制AQP1的功能来启动。